Redose
BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide derived from a protein naturally present in human gastric juice. It has attracted significant research interest for its reported ability to accelerate tissue repair across multiple biological systems, including tendons, muscles, and the gastrointestinal tract. It is an investigational compound with no current approval for human use from the FDA or any other major regulatory body.
What is BPC-157
BPC-157 is a 15-amino-acid peptide synthesized in the laboratory and based on a partial sequence of a human gastric protein. Unlike many peptides studied in regenerative medicine, it appears to be stable under acidic conditions, which has fueled interest in oral administration for gut-related applications in addition to injectable routes.
The compound has been studied primarily in rodent models since the 1990s. A very limited number of small human studies have been conducted, including an early-phase pharmacokinetics trial using intravenous administration. In that trial, two healthy adult participants received doses up to 20 mg and the treatment was reported as well tolerated, with plasma concentrations returning to baseline within 24 hours. This is consistent with BPC-157's known short half-life of less than 30 minutes.
How it works
BPC-157 is thought to work through several overlapping mechanisms, though the full picture remains under investigation:
- Nitric oxide modulation: It positively interacts with nitric oxide synthase (NOS), which regulates vascular tone, inflammation, and tissue repair signaling.
- Angiogenesis: It appears to stimulate growth of new blood vessels in wound healing contexts, partly through interaction with vascular endothelial growth factor (VEGF) receptors.
- Growth hormone receptor upregulation: Studies in tendon fibroblasts found that BPC-157 increased the expression of growth hormone receptors, which may contribute to tissue remodeling.
- Antioxidant enzyme induction: It influences heme oxygenase (HO-1) and other antioxidant pathways, reducing oxidative stress at injury sites.
- Neurotransmitter modulation: Some preclinical work points to effects on serotonin synthesis and interactions with GABA-A receptors, suggesting potential relevance to neuroprotection and mood, though this remains speculative.
These mechanisms are not independent. Researchers describe BPC-157 as "pleiotropic," meaning a single compound acts through many pathways simultaneously, which makes it both scientifically interesting and difficult to characterize cleanly.
What the research says
The overwhelming majority of BPC-157 research has been conducted in animal models, primarily rats and mice, across several areas:
| Area | Preclinical findings |
|---|---|
| Tendon and ligament | Improved tendon-to-bone healing, increased collagen production |
| Muscle | Enhanced fiber regeneration, reduced recovery time in injury models |
| Gastrointestinal | Protection of gastric mucosa, preserved gut lining integrity in colitis models |
| Bone | Some evidence of improved fracture healing in animal studies |
| Nerve | Accelerated recovery after sciatic nerve injury in rat models |
The gastrointestinal findings are among the most consistently replicated in the preclinical literature. Studies in animal models of ulcerative colitis, gastric ulcers, and NSAID-induced gut damage have reported protective effects on the mucosal lining.
A 2025 narrative review published in PMC (Current Reviews in Musculoskeletal Medicine) concluded that while the preclinical evidence is robust, "BPC-157 should be considered investigational" until well-designed human trials are conducted. The same review underscored that rigorous, large-scale randomized controlled trials are still lacking, which means efficacy and safety in humans cannot be confirmed.
There are also emerging safety signals worth noting. Some researchers have flagged that BPC-157 activates cellular pathways (including the FAK-paxillin pathway) that, in theory, could interact with tumor biology, though this has not been demonstrated in humans. This concern remains hypothetical but is a reason why caution and medical supervision are warranted.
If you are comparing this class of compound to other peptides, see the injection site rotation guide for practical notes on subcutaneous administration.
Typical dosing
There is no standardized, clinically validated dosing protocol for BPC-157 in humans. The ranges below are commonly reported in research literature and informal clinical wellness settings. They are provided here as reference information only, not as instructions.
| Use case | Reported route | Reported daily range | Reported cycle |
|---|---|---|---|
| Tendon or joint healing | Subcutaneous or intramuscular | 250-500 mcg | 2-6 weeks |
| Muscle recovery | Subcutaneous | 250-750 mcg | 2-4 weeks |
| Gut health | Oral capsule or subcutaneous | 250-500 mcg | 4-6 weeks |
| Neurological support | Subcutaneous (systemic) | 200-500 mcg | 4-8 weeks |
Subcutaneous injection near the injury site is the most commonly described route for musculoskeletal applications. Oral administration has been explored for gastrointestinal indications, though bioavailability via this route is debated in the literature. For guidance on preparing peptide solutions, see how to reconstitute peptides.
Important: BPC-157 is not approved for human use. Any use outside of a regulated clinical trial occurs outside established medical frameworks. Dosing decisions should only be made in consultation with a qualified healthcare provider.
Side effects and safety
The available human safety data for BPC-157 is limited to a very small number of participants. In the published pharmacokinetics study, intravenous administration up to 20 mg was reportedly well tolerated with no clinically meaningful changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers.
Commonly reported issues in informal use settings include:
- Injection site redness, swelling, or irritation
- Mild gastrointestinal discomfort (especially with oral use)
- Occasional dizziness or lightheadedness reported anecdotally
Because BPC-157 has a very short half-life (under 30 minutes), it is unlikely to accumulate with standard dosing intervals. However, the short half-life also means that efficacy in humans at practical doses remains uncertain, and the gap between animal study doses (often expressed in mcg/kg in rodents) and human extrapolations is not well bridged by existing clinical data.
Long-term safety in humans is unknown. Given the FDA's 2023 restriction on compounded use and WADA's classification as a banned substance, anyone considering BPC-157 should be aware of both the regulatory context and the absence of long-term human data.
Tracking BPC-157 with Redose
If you are running a BPC-157 protocol under medical supervision, Redose is designed to handle exactly this kind of multi-week injectable schedule. The app logs each dose in one tap, tracks remaining vial inventory with a visual progress bar, rotates injection sites automatically, and sends discreet reminders so you never miss a window. The free reconstitution calculator at /calculators converts vial size and BAC water volume into per-dose concentration and syringe units instantly. Download Redose at /#download for iPhone and Android.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.